Wipfli Financial Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Wipfli Financial Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$17K	Buy	+661	New	+$24.3K	﹤0.01%	1640

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wipfli Financial Advisors's EGRX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022: 661 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #1640 among its holdings.

153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

Wipfli Financial Advisors held 661 shares of Eagle Pharmaceuticals, Inc. worth $17K as of Q3 2022.
Eagle Pharmaceuticals, Inc. was a new Wipfli Financial Advisors position in Q3 2022.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1640 holding.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.